HCPCS Q5111
Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg (CMS descriptor)
Drugs Drug code Work RVU per service none (2023 fee schedule; adds 0 work RVUs)
Trend
Medicare payment on the code
Source: CMS Medicare Physician & Other Practitioners public use files (Original Medicare Part B fee-for-service). Data years 2020–2024.
Billers
Source: CMS Medicare Physician & Other Practitioners public use files (Original Medicare Part B fee-for-service). Data years 2020–2024.
| observed | calculated | calculated | calculated | calculated | calculated | reported | |
|---|---|---|---|---|---|---|---|
| 2024 | 179 | $8,495,188 | +4% | 76,981 | 360 | 912 | 0.00 |
| 2023 | 123 | $8,207,366 | -46% (2023 changed hospital and observation visit codes) | 76,340 | 472 | 1,389 | 0.00 |
| 2022 | 173 | $15,085,669 | -28% | 107,160 | 480 | 1,536 | 0.00 |
| 2021 | 221 | $20,982,530 | – (Not compared: 2021 changed office visit values) | 107,009 | 408 | 948 | 0.00 |
| 2020 | 251 | $34,385,046 | first year in data | 140,545 | 468 | 1,122 | 0.00 |
Source: CMS Medicare Physician & Other Practitioners public use files (Original Medicare Part B fee-for-service). Data years 2020–2024.
By state
| observed | calculated | calculated | calculated | calculated | calculated | |
|---|---|---|---|---|---|---|
| New Jersey | 46 | $3,523,320 | 33,034 | 579 | 1,491 | |
| Maryland | 11 | $1,020,014 | 9,425 | 934 | 1,440 | |
| Illinois | 13 | $863,053 | 7,957 | 432 | 1,371 | |
| New York | 16 | $813,838 | 7,500 | 402 | 840 |
Not listed: 13 states with fewer than 11 billers (small cells).
Source: CMS Medicare Physician & Other Practitioners public use files (Original Medicare Part B fee-for-service). Providers placed by practice address. Data year 2023.
Top metro areas
| observed | calculated | calculated | calculated | calculated | |
|---|---|---|---|---|---|
| New York-Newark-Jersey City, NY-NJ | 36 | $3,048,499 | 28,597 | 624 |
Source: CMS Medicare Physician & Other Practitioners public use files (Original Medicare Part B fee-for-service). The 1 areas with the most payment among those with at least 11 billers; non-metro parts of each state are one area. Data year 2023.
Specialties billing Q5111 nationally
Hematology-Oncology accounts for 79% of payment for Q5111 nationally in 2023, across 2 specialties on claims.
| observed | calculated | calculated | calculated | calculated | calculated | |
|---|---|---|---|---|---|---|
| Hematology-Oncology | 92 | 75% | $6,468,744 | 79% | 60,193 | 654 |
| Medical Oncology | 14 | 11% | $724,869 | 8.8% | 6,732 | 481 |
Not listed: 5 specialties with fewer than 11 billers (small cells).
Source: CMS Medicare Physician & Other Practitioners public use files (Original Medicare Part B fee-for-service). Provider-level lines (fewer than 11 beneficiaries suppressed by CMS); specialty is the provider type on claims. Data year 2023.
Top billers of Q5111 nationally
Named top billers are a Pro figure, and Pro is not available to buy, so this list is not shown to any account. The counts and totals by state, metro area and specialty on this page are free.
Original Medicare Part B fee-for-service only; CMS suppresses provider lines with fewer than 11 beneficiaries. How these figures are computed · Limitations